Andrius Giedraitis
Pain Medicine · Findlay, OHNPI 1689088973
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,687 of the $7,531 with a category attached, or 62.2%. Boston Scientific accounts for 67.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $2,401 and has fallen 66.7% since, to $800 in 2025.
Across 122 payments — averaging $61.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Medtronic$2K
- Nevro Corp.$552
- Averitas Pharma Inc.$31
What the payments were for
- Travel & lodging$2,84338%
- Food & beverage$4,68762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 96 | $5,063 |
| Medtronic(2 entities) | 20 | $1,885 |
| Nevro Corp. | 4 | $552 |
| Averitas Pharma Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,531 in reported general payments places this provider in the 75th percentile of 245 pain medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 53 | $9,924 |
| Xtampza ErOxycodone Myristate | 11 | $9,839 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 313 | $6,750 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 357 | $6,280 |
| Gabapentin | 347 | $4,215 |
| Pregabalin | 135 | $4,131 |
| Celecoxib | 65 | $2,602 |
| Tramadol Hcl | 256 | $1,559 |
| Lidocaine | 17 | $1,188 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 66 | $1,135 |
| Zonisamide | 37 | $889 |
| Baclofen | 122 | $850 |
| Morphine Sulfate ErMorphine Sulfate | 18 | $645 |
| Tizanidine Hcl | 72 | $550 |
| Duloxetine Hcl | 40 | $516 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Findlay
- Alexander EscobarToledo$638K
- Nagy MekhailCleveland$511K
- Henry VuceticWilloughby$509K
- Tammy DannDayton$431K
- Michael DankoLoveland$381K
- Jonathan SilvermanDayton$234K
- Tristan WeaverColumbus$202K
- Robert BolashCleveland$154K
- Dmitri SouzaCuyahoga Falls$61K
- Aman UpadhyayCleveland$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.